CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is a peptide combination designed to stimulate the body’s own growth-hormone signaling. CJC-1295 is a growth-hormone-releasing-hormone analog, while Ipamorelin activates the ghrelin receptor to trigger growth-hormone release. Because the two work through different receptors, they are commonly paired in clinician-guided wellness protocols. CJC-1295 produced sustained, dose-dependent increases in growth hormone and IGF-1 in healthy adults clinical study, while Ipamorelin produced a clear growth-hormone response in healthy volunteers human PK/PD study. The combination is intended to support recovery, sleep quality, lean-body-mass goals, and body composition, although it has less direct clinical-outcome data than the individual peptides.

CJC-1295 + Ipamorelin works by increasing endogenous growth-hormone signaling rather than providing growth hormone directly. CJC-1295 extends stimulation of the GHRH pathway and has been shown to raise both GH and IGF-1 over multiple days in human studies study. Ipamorelin creates a more immediate GH secretory response through the ghrelin receptor study. That physiology is used to support recovery, sleep, body-composition, and lean-mass goals. Those outcomes are not automatic: adequate protein, resistance training, sleep, and overall metabolic health strongly influence whether the patient sees a meaningful change.

CJC-1295 + Ipamorelin can be appropriate for selected patients under clinician supervision, but increasing growth hormone and IGF-1 is not desirable for everyone. Your clinician will review glucose regulation, cancer history, pituitary or endocrine conditions, pregnancy status, other hormone therapies, and any overlapping growth-hormone-axis peptides before treatment. Possible effects can include injection-site irritation, headache, flushing, tingling, fluid retention, or changes in glucose handling. Any persistent or concerning symptom should be reviewed by the prescribing clinician.

Our CJC-1295 + Ipamorelin uses CJC-1295 without DAC. No DAC is shorter acting and is designed to support a more pulsatile growth hormone response, rather than the prolonged stimulation associated with CJC-1295 with DAC. Our standard protocol uses daily subcutaneous injections Monday through Friday. When medically appropriate, treatment is typically cycled for 3 months on, followed by 1 month off. Your provider will determine the appropriate dose, treatment duration, and cycle based on your individual medical history and response to treatment.

CJC-1295 + Ipamorelin can affect GH/IGF-1 signaling within days, but patient-visible effects take longer. Sleep or recovery changes may be noticed within about 1–3 weeks, while body-composition changes are more reasonably evaluated after 8–12 weeks. Fuller changes in lean mass or fat distribution may require 3–6 months of consistent treatment and training.

Bowery Clinic peptides are higher-strength and clinically dosed compared to most research facilities that use much lower concentrations. They are compounded by licensed 503A pharmacies with physician oversight and sterile quality standards, prioritizing real therapeutic outcomes over cheaper, unregulated research-grade products, and come fully prepared and ready for use — no mixing or reconstitution needed.

Yes. All pharmacies in our network are fully licensed in the states where they operate and comply with all state board of pharmacy regulations. Unlike many peptide clinics, we partner exclusively with FDA-registered U.S. pharmacies that undergo rigorous evaluation and compliance checks.

Every patient receives treatment plans developed and monitored by licensed providers. This includes safe titration of dosages and ongoing medical oversight tailored to individual needs.

Injections deliver the medication directly into your system. This makes the absorption more consistent and effective. Troches are small dissolvable lozenges that sit in your mouth until they melt, slowly releasing medication through the lining of your cheek or under your tongue.